Tebbe 2009

1 Treatments

Studied treatment 125, 180, and 250 microg/kg bodyweight desmoteplase

Control treatment 100 mg alteplase

Concomittant treatments -

treatment duration (days) -

female (%) -

Age (mean), years -

2 Patients

Patients acute massive pulmonary thromboembolism

Inclusion criteria -

Exclusion criteria -

3 Methods

Blinding NA

Design Parallel groups

Centers -

Geographical area -

Sizes 34/0

Systolic blood pressure -

Diastolic blood pressure -

delay from onset -

diagnostic test -
4 Results

<table>
<thead>
<tr>
<th>Endpoint</th>
<th>T1</th>
<th>T0</th>
<th>d</th>
<th>95% CI</th>
</tr>
</thead>
<tbody>
<tr>
<td>minor bleeding</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>All cause death</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>recurrence of pulmonary embolism</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
<tr>
<td>major bleeding</td>
<td>-/-9</td>
<td>-/-9</td>
<td>NA</td>
<td>-</td>
</tr>
</tbody>
</table>

5 References